These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 17342521)

  • 1. Fractures in children with Pompe disease: a potential long-term complication.
    Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
    Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
    Hamdan MA; Almalik MH; Mirghani HM
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
    Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
    Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
    Pascual SI
    Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
    Ertoy Karagol HI; Inci A; Terece SP; Kilic A; Demir F; Yapar D; Koken G; Okur I; Ezgu FS; Tumer L; Bakirtas A;
    Int Arch Allergy Immunol; 2023; 184(4):370-375. PubMed ID: 36623499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.